Harold Hubert, MD
Nephrology · Augusta, GANPI 1417171307
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,707 of the $6,846 with a category attached, or 83.4%. It is spread thinly across 28 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,400 and has fallen 60.2% since, to $954 in 2025.
Across 298 payments — averaging $22.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$2K
- AstraZeneca$654
- Amgen$635
- Akebia Therapeutics Inc$511
- Calliditas Therapeutics US Inc.$413
- Vifor Pharma, Inc.$385
- plus $3K from 22 others
Across 1,111 payments — averaging $2503.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$2.4M
- Astrazeneca UK Limited$411K
What the payments were for
- Travel & lodging$85412%
- Food & beverage$5,70783%
- Education$2854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 27 | $1,522 |
| AstraZeneca(2 entities) | 38 | $654 |
| Amgen(2 entities) | 29 | $635 |
| Akebia Therapeutics Inc | 23 | $511 |
| Calliditas Therapeutics US Inc. | 19 | $413 |
| Vifor Pharma, Inc. | 23 | $385 |
| Mallinckrodt Hospital Products Inc. | 14 | $363 |
| Otsuka America Pharmaceutical, Inc. | 14 | $340 |
| OPKO Pharmaceuticals, LLC | 16 | $282 |
| Aurinia Pharma U.S., Inc. | 14 | $245 |
| GSK | 13 | $221 |
| Fresenius USA Marketing, Inc. | 13 | $218 |
| Novartis | 9 | $195 |
| Travere Therapeutics, Inc. | 13 | $175 |
| Boehringer Ingelheim | 7 | $136 |
| Daiichi Sankyo Inc. | 5 | $103 |
| Ardelyx, Inc. | 5 | $95 |
| Lilly USA, LLC | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Baxter Healthcare | 2 | $63 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Novo Nordisk | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Merck | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
| Boston Scientific | 1 | $12 |
How this compares
$6,846 in reported general payments places this provider in the 85th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 102 | $90,278 |
| KerendiaFinerenone | 68 | $84,930 |
| XphozahTenapanor Hcl | 12 | $82,509 |
| BenlystaBelimumab | 13 | $68,839 |
| VeltassaPatiromer Calcium Sorbitex | 22 | $23,763 |
| JardianceEmpagliflozin | 13 | $11,192 |
| Sevelamer Carbonate | 94 | $11,173 |
| JanuviaSitagliptin Phosphate | 12 | $5,827 |
| Calcitriol | 234 | $4,800 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 176 | $3,380 |
| Hydralazine Hcl | 167 | $3,310 |
| Carvedilol ErCarvedilol Phosphate | 13 | $2,956 |
| Eplerenone | 33 | $2,949 |
| Furosemide | 277 | $2,326 |
| Losartan Potassium | 241 | $2,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $654 | $90,278102 claims |
| BayerKerendia | $1,522 | $84,93068 claims |
| GSKBenlysta | $221 | $68,83913 claims |
| Boehringer IngelheimJardiance | $136 | $11,19213 claims |
| MerckJanuvia | $20 | $5,82712 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $18 | $29529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 388 nephrology providers in Georgia.
Other nephrology in Augusta
- Don WilliamsonAugusta$104K
- Barton BrezinaAugusta$47K
- Matthew DiamondAugusta$14K
- Laura MulloyAugusta$11K
- Syed BabarAugusta$8K
- Muralidharan JagadeesanAugusta$8K
- Shameem BeighAugusta$7K
- Devesh PatelAugusta$6K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.